Cutting Edge: LAG3 Dimerization Is Required for TCR/CD3 Interaction and Inhibition of Antitumor Immunity
The Journal of Immunology · 2024
DOI: 10.4049/jimmunol.2300673 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, 2024. Verfasst von Kieran Adam und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA. Hauptthemen laut MEDLINE: Lymphocyte Activation Gene 3 Protein, Antigens, CD, Protein Multimerization, CD8-Positive T-Lymphocytes. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NCI NIH HHS, HHS | NIH | National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Lymphocyte activation gene 3 (LAG3) is an inhibitory receptor that plays a critical role in controlling T cell tolerance and autoimmunity and is a major immunotherapeutic target. LAG3 is expressed on the cell surface as a homodimer but the functional relevance of this is unknown. In this study, we show that the association between the TCR/CD3 complex and a murine LAG3 mutant that cannot dimerize is perturbed in CD8+ T cells. We also show that LAG3 dimerization is required for optimal inhibitory function in a B16-gp100 tumor model. Finally, we demonstrate that a therapeutic LAG3 Ab, C9B7W, which does not block LAG3 interaction with its cognate ligand MHC class II, disrupts LAG3 dimerization and its association with the TCR/CD3 complex. These studies highlight the functional importance of LAG3 dimerization and offer additional approaches to therapeutically target LAG3.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA.
- Tumor Microenvironment Center, University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA.
- W. M. Keck Laboratory for Structural Biology, University of Maryland Institute for Biosciences and Biotechnology Research, Rockville, MD.
- Department of Cell Biology and Molecular Genetics, University of Maryland, College Park, MD.
- Cancer Immunology and Immunotherapy Program, University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA.
ORCID-Profile: Kieran Adam, Dario A A Vignali
Förderung
- NIAID NIH HHS
- NCI NIH HHS
- HHS | NIH | National Institute of Allergy and Infectious Diseases
Zitieren
APA
Adam, K., Lipatova, Z., Abdul Ghafoor Raja, M., Mishra, A. K., Mariuzza, R. A., Workman, C. J., & Vignali, D. A. A. (2024). Cutting Edge: LAG3 Dimerization Is Required for TCR/CD3 Interaction and Inhibition of Antitumor Immunity. The Journal of Immunology. https://doi.org/10.4049/jimmunol.2300673
Vancouver
Adam K, Lipatova Z, Abdul Ghafoor Raja M, Mishra AK, Mariuzza RA, Workman CJ, et al. Cutting Edge: LAG3 Dimerization Is Required for TCR/CD3 Interaction and Inhibition of Antitumor Immunity. The Journal of Immunology. 2024. doi:10.4049/jimmunol.2300673
BibTeX
@article{Adam2024,
author = {Adam, Kieran and Lipatova, Zhanna and Abdul Ghafoor Raja, Maria and Mishra, Arjun K and Mariuzza, Roy A and Workman, Creg J and Vignali, Dario A A},
title = {Cutting Edge: LAG3 Dimerization Is Required for TCR/CD3 Interaction and Inhibition of Antitumor Immunity},
journal = {The Journal of Immunology},
year = {2024},
doi = {10.4049/jimmunol.2300673}
}
EUVIMED